Lipoprotein(A)

Clinical Lipidology: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2009, Pages 130-143

  Koschinsky, Marlys L ^a   Marcovina, Santica M ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 78649836618     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605469-6.50015-9     Document Type: Chapter

References (138)

1. Berg K A new serum type system in man: The Lp system. Acta Pathol Microbiol Scand 1963, 59:362-382.
2. Kraft HG, Menzel HJ, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989, 83:137-142.
3. Koschinsky ML, Côté GP, Gabel BR, van der Hoek YY Identification of the cysteine residue in apolipoprotein(a) that mediates extracellular coupling with apolipoprotein B-100. J Biol Chem 1993, 268:19819-19825.
4. Albers JJ, Kennedy H, Marcovina SM Evidence that Lp(a) contains one molecule of apo(a) and one molecule of apo B: Evaluation of amino acid analysis data. J Lipid Res 1996, 37:192-196.
5. Koschinsky ML, Marcovina SM Structure-function relationships in apolipoprotein(a): Insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004, 15:167-174.
6. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987, 330:132-137.
7. Lackner C, Cohen JC, Hobbs HH Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet 1993, 2:933-940.
8. van der Hoek YY, Wittekoek ME, Beisiegel U, et al. The apolipoprotein(a) kringle IV repeats which differ from the major repeat kringle are present in variably sized isoforms. Hum Mol Genet 1993, 2:361-366.
9. Marcovina SM, Hobbs HH, Albers JJ Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: Basis for a standardized isoform nomenclature. Clin Chem 1996, 42:436-439.
10. Becker L, Cook PM, Wright TG, Koschinsky ML Quantitative evaluation of the contribution of weak lysine-binding sites present within apolipoprotein(a) kringle IV types 6-8 to lipoprotein(a) assembly. J Biol Chem 2004, 279:2679-2688.
11. Callow MJ, Rubin EM Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein(a) in vivo. J Biol Chem 1995, 270:23914-23917.
12. Sangrar W, Marcovina SM, Koschinsky ML Expression and characterization of apolipoprotein(a) kringle IV types 1, 2 and 10 in mammalian cells. Protein Eng 1993, 7:723-731.
13. Scanu AM Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med 1988, 112:1045-1047.
14. Fless GM, ZumMallen ME, Scanu AM Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein(a). J Biol Chem 1986, 261:8712-8718.
15. Rader DJ, Cain W, Ikewaki K, et al. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest 1994, 93:2758-2763.
16. Boerwinkle E, Leffert CC, Lin J, et al. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1990, 90:52-60.
17. Angelin B Therapy for lowering lipoprotein (a) levels. Curr Opin Lipidol 1997, 8:337-341.
18. Anuurad E, Boffa MB, Koschinsky ML, Berglund L Lipoprotein(a): A unique risk factor for cardiovascular disease. Clin Lab Med 2006, 26:751-772.
19. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions. Clin Chem 2003, 49:1785-1796.
20. Utermann G, Menzel HJ, Kraft HG, et al. Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest 1987, 80:458-465.
21. Brunner C, Lobentanz EM, Petho-Schramm A, et al. The number of identical kringle IV repeats in apolipoprotein(a) affects its processing and secretion by HepG2 cells. J Biol Chem 1996, 271:32403-32410.
22. White AL, Rainwater DL, Lanford RE Intracellular maturation of apolipoprotein(a) and assembly of lipoprotein(a) in primary baboon hepatocytes. J Lipid Res 1993, 34:509-517.
23. Marcovina SM, Albers JJ, Wijsman, et al. Differences in Lp(a) concentrations and apo(a) polymorphs between black and white Americans. J Lipid Res 1996, 37:2569-2585.
24. Anuurad E, Lu G, Rubin J, et al. ApoE genotype affects allele-specific apo[a] levels for large apo[a] sizes in African Americans: The Harlem-Basset Study. J Lipid Res 2007, 48:693-698.
25. Chretien JP, Coresh J, Berthier-Schaad Y, et al. Three single-nucleotide polymorphisms in LPA account for most of the increase in lipoprotein(a) level elevation in African Americans compared with European Americans. J Med Genet 2006, 43:917-923.
26. Rubin J, Paultre F, Tuck CH, et al. Apolipoprotein(a) genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res 2002, 43:234-244.
27. Berglund L, Ramakrishnan R Lipoprotein(a). An elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004, 24:2219-2226.
28. Paultre F, Pearson TA, Weil HF, et al. High levels of Lp(a) with a small apo(a) isoform are associated with coronary artery disease in African American and White men. Arterioscler Thromb Vasc Biol 2000, 20:2619-2624.
29. Kostner KM, Clodi M, Bodlaj G, et al. Decreased urinary apolipoprotein(a) excretion in patients with impaired renal function. Eur J Clin Invest 1998, 28:447-452.
30. Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998, 129:457-461.
31. Frischmann ME, Kronenberg F, Trenkwalder E, et al. In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients. Kidney Int 2007, 71:1036-1043.
32. Cain WJ, Millar JS, Himebauch AS, et al. Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005, 46:2681-2691.
33. Kostner KM, Maurer G, Huber K, et al. Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol 1996, 16:905-911.
34. Hrzenjak A, Frank S, Wo X, et al. Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism. Biochem J 2003, 376:765-771.
35. Floren CH, Albers JJ, Bierman EL Uptake of Lp (a) lipoprotein by cultured fibroblasts. Biochem Biophys Res Commun 1981, 102:636-639.
36. Havekes L, Vermeer BJ, Brugman T, Emeis J Binding of LP(a) to the low-density lipoprotein receptor of human fibroblasts. FEBS Lett 1981, 132:169-173.
37. Krempler F, Kostner GM, Roscher A, et al. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest 1983, 71:1431-1441.
38. Mbewu AD, Bhatnagar D, Durrington PN, et al. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler Thromb 1991, 11:940-946.
39. Utermann G, Hoppichler F, Dieplinger H, et al. Defects in the low-density lipoprotein receptor gene affect lipoprotein (a) levels: Multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci USA 1989, 86:4171-4174.
40. Marz W, Beckmann A, Scharnagl H, et al. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low-density lipoprotein receptor and the low-density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett 1993, 325:271-275.
41. Rader DJ, Mann WA, Cain W, et al. The low-density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995, 95:1403-1408.
42. Lawn RM How often has Lp(a) evolved?. Clin Genet 1996, 49:167-174.
43. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:: Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
44. Aboyans V, Criqui MH, Denenberg JO, et al. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation 2006, 113:2623-2639.
45. Cheng SW, Ting AC, Wong J Lipoprotein(a) and its relationship to risk factors and severity of atherosclerotic peripheral vascular disease. Eur Vasc Endovasc Surg 1997, 14:17-23.
46. Ohira T, Schreiner PJ, Morrisett JD, et al. Lipoprotein(a) and incident ischemic stroke: The Atherosclerosis Risk in Communities (ARIC) study. Stroke 2006, 37:1407-1412.
47. Peng DQ, Zhao SP, Wang JL Lipoprotein(a) and apolipoprotein E epsilon 4 as independent risk factors for ischemic stroke. J Cardiovasc Risk 1999, 6:1-6.
48. Jones GT, van Rij AM, Cole J, et al. Plasma lipoprotein(a) indicates risk for 4 distinct forms of vascular disease. Clin Chem 2007, 53:679-685.
49. Koschinsky ML Lipoprotein(a) and atherosclerosis: New perspectives on the mechanism of action of an enigmatic lipoprotein. Curr Atheroscler Rep 2005, 7:389-395.
50. Genest J, Jenner JL, McNamara JR, et al. Prevalence of lipoprotein (a) [Lp(a)] excess in coronary artery disease. Am J Cardiol 1991, 67:1039-1145.
51. Assmann G, Schulte H, von-Eckardstein A Hypertriglyceridemia and elevated lipoprotein(a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 1996, 77:1179-1184.
52. Bostom AG, Gagnon DR, Cupples LA, et al. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women. The Framingham Heart Study. Circulation 1994, 90:1688-1695.
53. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996, 276:544-548.
54. Sigurdsson G, Baldursdottir A, Sigvaldason H, et al. Predictive value of apolipoproteins in a prospective survey of coronary artery disease in men. Am J Cardiol 1992, 69:1251-1254.
55. Wald NJ, Law M, Watt HC, et al. Apolipoproteins and ischaemic heart disease: Implications for screening. Lancet 1994, 343:75-79.
56. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1996, 271:999-1003.
57. Jauhiainen M, Koskinen P, Ehnholm C, et al. Lipoprotein (a) and coronary heart disease risk: A nested case-control study of the Helsinki Heart Study participants. Atherosclerosis 1991, 89:59-67.
58. Ridker PM, Hennekens CH, Stampfer MJ A prospective study of lipoprotein(a) and the risk of myocardial infarction. JAMA 1993, 270:2195-2199.
59. Craig WY, Neveux LM, Palomaki GE, et al. Lipoprotein(a) as a risk factor for ischemic heart disease: Meta-analysis of prospective studies. Clin Chem 1998, 44:2301-2306.
60. Danesh J, Collins R, Peto R Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000, 102:1082-1085.
61. Sharrett AR, Ballantyne CM, Coady SA, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001, 104:1108-1113.
62. Glader CA, Birgander LS, Stenlund H, Dahlen GH Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002, 252:27-35.
63. Maher VM, Brown BG, Marcovina SM, et al. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). J Am Med Assoc 1995, 274:1771-1774.
64. Luc G, Bard JM, Arveiler D, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis 2002, 163:377-384.
65. Cantin B, Gagnon F, Moorjani S, et al. Is lipoprotein(a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. J Am Coll Cardiol 1998, 31:519-525.
66. von-Eckardstein A, Schulte H, Cullen P, Assmann G Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol 2001, 37:434-439.
67. Suk Danik J, Rifai N, Buring JE, Ridker PM Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA 2006, 296:1363-1370.
68. Dahlen GH, Guyton JR, Attar M, et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986, 74:758-765.
69. Kronenberg F, Kronenberg MF, Kiechl S, et al. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis: Prospective results from the Bruneck study. Circulation 1999, 100:1154-1160.
70. Paultre F, Tuck CH, Boden-Albala B, et al. Relation of apo(a) size to carotid atherosclerosis in an elderly multiethnic population. Arterioscler Thromb Vasc Biol 2002, 22:141-146.
71. Wild SH, Fortmann SP, Marcovina SM A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol 1997, 17:239-245.
72. Orth-Gomer K, Mittleman MA, Schenck-Gustafsson K, et al. Lipoprotein(a) as a determinant of coronary heart disease in young women. Circulation 1997, 95:329-334.
73. Shai I, Rimm EB, Hankinson SE, et al. Lipoprotein (a) and coronary heart disease among women: Beyond a cholesterol carrier?. Eur Heart J 2005, 26:1633-1639.
74. Ariyo AA, Thach C, Tracy R Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003, 349:2108-2115.
75. Ridker PM, Hennekens CH, Buring JE, Rifai N C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000, 342:836-843.
76. Wu HD, Berglund L, Dimayuga C, et al. High lipoprotein(a) levels and small apolipoprotein(a) sizes are associated with endothelial dysfunction in a multiethnic cohort. J Am Coll Cardiol 2004, 43:1828-1833.
77. Emanuele E, Peros E, Minoretti P, et al. Significance of apolipoprotein(a) phenotypes in acute coronary syndromes: Relation with clinical presentation. Clin Chim Acta 2004, 350:159-165.
78. Rifai N, Ma J, Sacks FM, et al. Apolipoprotein(a) size and lipoprotein(a) concentrations and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physician's Health Study. Clin Chem 2004, 50:1364-1371.
79. Rath M, Niendorf A, Reblin T, et al. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis 1989, 9:579-592.
80. Sangrar W, Bajzar L, Nesheim ME, Koschinsky ML Antifibrinolytic effect of recombinant apolipoprotein(a). in vitro is primarily due to attenuation of tPA-mediated Glu-plasminogen activation. Biochemistry 1995, 34:5151-5157.
81. Marcovina SM, Koschinsky ML Evaluation of lipoprotein(a) as a prothrombotic factor: Progress from bench to bedside. Curr Opin Lipidol 2003, 14:361-366.
82. O'Neil CH, Boffa MB, Hancock MA, et al. Stimulation of vascular smooth muscle cell proliferation and migration by apolipoprotein(a) is dependent on inhibition of transforming growth factor-beta activation and on the presence of kringle IV type 9. J Biol Chem 2004, 279:55187-55195.
83. Desmarais RL, Sarembock IJ, Ayers CR, et al. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation 1995, 91:1403-1409.
84. Pokrovsky SN, Ezhov MV, Il'ina LN, et al. Association of lipoprotein(a) excess with early vein graft occlusions in middle-aged men undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003, 126:1071-1075.
85. Undas A, Stepien E, Tracz W, Szczeklik A Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis. J Thromb Haemost 2006, 4:973-975.
86. Caplice NM, Panetta C, Peterson TE, et al. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis. Blood 2001, 98:2980-2987.
87. Rand ML, Sangrar W, Hancock MA, et al. Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN. Arterioscler Thromb Vasc Biol 1998, 18:1393-1399.
88. Pellegrino M, Furmaniak-Kazmierczak E, LeBlanc JC, et al. The apolipoprotein(a) component of lipoprotein(a) stimulates actin stress fiber formation and loss of cell-cell contact in cultured endothelial cells. J Biol Chem 2004, 279:6526-6533.
89. Allen S, Khan S, Tam S-P, et al. Expression of adhesion molecules by Lp(a): A potential novel mechanism for its atherogenicity. FASEB J 1998, 12:1765-1776.
90. Schachinger V, Halle M, Minners J, et al. Lipoprotein(a) selectively impairs receptor-mediated endothelial vasodilator function of the human coronary circulation. J Am Coll Cardiol 1997, 30:927-934.
91. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003, 41:360-370.
92. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): Short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004, 109:3164-3170.
93. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-physphatidylcholine adducts in kringle V impart unique immunological and protein pro-inflammatory properties to human apolipoprotein(a). J Biol Chem 2003, 278:52841-52847.
94. Boffa MB, Marcovina SM, Koschinsky ML Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: Mechanistic insights from animal models. Clin Biochem 2004, 37:333-343.
95. Fan J, Shimoyamada H, Sun H, et al. Transgenic rabbits expressing human apolipoprotein(a) develop more extensive atherosclerotic lesion in response to a cholesterol-rich diet. Arterioscler Thromb Vasc Biol 2001, 21:88-94.
96. Sun H, Unoki H, Wang X, et al. Lipoprotein(a) enhances advanced atherosclerosis and vascular calcification in WHHL transgenic rabbits expressing human apolipoprotein(a). J Biol Chem 2002, 277:47486-47492.
97. Guerra R, Yu Z, Marcovina S, et al. Lipoprotein(a) and apolipoprotein(a) isoforms: No association with coronary artery calcification in the Dallas Heart Study. Circulation 2005, 111:1471-1479.
98. Schneider M, Witztum JL, Young SG, et al. High-level lipoprotein(a) expression in transgenic mice: Evidence for oxidized phospholipids in lipoprotein(a) but not in low-density lipoproteins. J Lipid Res 2005, 46:769-778.
99. Devlin CM, Lee SJ, Kuriakose G, et al. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler Thromb Vasc Biol 2005, 25:1704-1710.
100. Kitajima S, Jin Y, Koike T, et al. Lp(a) enhances coronary atherosclerosis in transgenic Watanabe heritable hyperlipidemic rabbits. Atherosclerosis 2007, 193:269-276.
101. Kang C, Dominguez M, Loyau S, et al. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: A study with different-length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002, 22:1232-1238.
102. Anglés-Cano E, de la Peña Díaz A, Loyau S Inhibition of fibrinolysis by lipoprotein(a). Ann N Y Acad Sci 2001, 936:261-275.
103. Knapp JP, Herrmann W In vitro inhibition of fibrinolysis by apolipoprotein(a) and lipoprotein(a) is size- and concentration-dependent. Clin Chem Lab Med 2004, 42:1013-1019.
104. Baldo G, Giunco S, Kontothanassis D, et al. Different apoprotein(a) isoform proportions in serum and carotid plaque. Atherosclerosis 2007, 193:177-185.
105. Marcovina SM, Albers JJ, Scanu AM, et al. Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a). Clin Chem 2000, 46:1956-1967.
106. Tate JR, Berg K, Couderc R, et al. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Standardization Project for the Measurement of Lipoprotein(a). Phase 2: selection and properties of a proposed secondary reference material for lipoprotein(a). Clin Chem Lab Med 1999, 37:949-958.
107. Marcovina SM, Albers JJ, Gabel B, et al. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem 1995, 41:246-255.
108. Dati F, Tate JR, Marcovina SM, Steinmetz A First WHO/IFCC International Reference Reagent for Lipoprotein(a) for Immunoassay-Lp(a) SRM 2B. Clin Chem Lab Med 2004, 42:670-676.
109. Edelstein C, Hinman J, Marcovina S, Scanu AM Properties of human free apolipoprotein(a) and lipoprotein(a) after either freezing or lyophilization in the presence and absence of cryopreservatives. Anal Biochem 2001, 288:201-208.
110. Scanu AM, Hinman J, Pfaffinger D, Edelstein C Successful utilization of lyophilized lipoprotein(a) as a biological reagent. Lipids 2004, 39:589-593.
111. Kulkarni KR, Garber DW, Marcovina SM, Segrest JP Quantification of cholesterol in all lipoprotein classes by the VAP-II method. J Lipid Res 1994, 35:159-168.
112. Seman LJ, Jenner JL, McNamara JR, Schaefer EJ Quantification of lipoprotein(a) in plasma by assaying cholesterol in lectin-bound plasma fraction. Clin Chem 1994, 40:400-403.
113. Baudhuin LM, Hartman SJ, O'Brien JF, et al. Electrophoretic measurement of lipoprotein(a) cholesterol in plasma with and without ultracentrifugation: Comparison with an immunoturbidimetric lipoprotein(a) method. Clin Biochem 2004, 37:481-488.
114. Marcovina SM, Koschinsky ML Lipoprotein(a): Structure, measurement and clinical significance. Handbook of Lipoprotein Testing 2000, 345-385. AACC Press, Washington, DC. 2nd ed. N. Rifai, G.R. Warnick, M.H. Dominiczak (Eds.).
115. Armstrong VW, Schleef J, Thiery J, et al. Effect of HELP-LDL-apheresis on serum concentrations of human lipoprotein(a): Kinetic analysis of the post-treatment return to baseline levels. Eur J Clin Invest 1989, 19:235-240.
116. Pokrovsky SN, Adamova I, Afanasieva OY, Benevolenskaya GF Immunosorbent for selective removal of lipoprotein(a) from human plasma: (i)in vitro(/i) study. Artif Organs 1991, 15:136-140.
117. Crouse JR New developments in the use of niacin for treatment of hyperlipidemia: New considerations in the use of an old drug. Coron Artery Dis 1996, 7:321-326.
118. Sirtori CR, Calabresi L, Ferrara S, et al. L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). Nutr Metab Cardiovasc Dis 2000, 10:247-251.
119. Dalessandri KM Multiple methods for reduction of lipoprotein(a). Atherosclerosis 2002, 163:409-410.
120. McCormack PL, Keating GM Prolonged-release nicotinic acid: A review of its use in the treatment of dyslipidaemia. Drugs 2005, 65:2719-2740.
121. Crook D, Sidhu M, Seed M, et al. Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid. Atherosclerosis 1992, 92:41-47.
122. Haenggi W, Riesen W, Birkhaeuser MH Postmenopausal hormone replacement therapy with tibolone decreases serum lipoprotein(a). Eur J Clin Chem Clin Biochem 1993, 31:645-650.
123. Rymer J, Crook D, Sidhu M, et al. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. Acta Endocrinol 1993, 128:259-262.
124. Henriksson P, Angelin B, Berglund L Hormonal regulation of serum Lp(a) levels. Opposite effects after estrogen treatment and orchidectomy in males with prostatic carcinoma. J Clin Invest 1992, 89:1166-1171.
125. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994, 14:1586-1593.
126. Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: An effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447-1452.
127. Dujovne CA, Harris WS, Altman R, et al. Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients. Am J Cardiol 2000, 85:350-353.
128. McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis 2007, 192:432-437.
129. Cobbaert C, Jukema JW, Zwinderman AH, et al. Modulation of lipoprotein(a) atherogenicity by high-density lipoprotein cholesterol levels in middle-aged men with symptomatic coronary artery disease and normal to moderately elevated serum cholesterol. Regression Growth Evaluation Statin Study (REGRESS) Study Group. J Am Coll Cardiol 1997, 30:1491-1499.
130. Duriez P, Dallongeville J, Fruchart JC Lipoprotein(a) as a marker for coronary heart disease. Br J Clin Pract 1996, 77A:54-61.
131. Gonbert S, Malinsky S, Sposito AC, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis 2002, 164:305-311.
132. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002, 48:1454-1459.
133. Kiortsis DN, Tzotzas T, Giral P, et al. Changes in lipoprotein(a) levels and hormonal correlations during a weight reduction program. Nutr Metab Cardiovasc Dis 2001, 11:153-157.
134. Jenkins DJ, Kendall CW, Marchie A, et al. Dose response of almonds on coronary heart disease risk factors: Blood lipids, oxidized low-density lipoproteins, lipoprotein(a), homocysteine, and pulmonary nitric oxide: A randomized, controlled, crossover trial. Circulation 2002, 106:1327-1332.
135. Ginsberg HN, Kris-Etherton P, Dennis B, et al. Effects of reducing dietary saturated fatty acids on plasma lipids and lipoproteins in healthy subjects: The DELTA Study, protocol 1. Arterioscler Thromb Vasc Biol 1998, 18:441-449.
136. Meinertz H, Nilausen K, Hilden J Alcohol-extracted, but not intact, dietary soy protein lowers lipoprotein(a) markedly. Arterioscler Thromb Vasc Biol 2002, 22:312-316.
137. White AL, Lanford RE Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol 1995, 6:75-80.
138. Assmann G, Cullen P, Fruchart JC, et al. Implications of emerging risk factors for therapeutic intervention. International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis 2005, 15:373-381.